MENSA
Mepolizumab Treatment in Severe Eosinophilic Asthma
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 576 patients with severe eosinophilic asthma, subcutaneous mepolizumab 100 mg every 4 weeks reduced exacerbations compared with placebo.
N
576
Design
Multicentre phase-3 RCT
Endpunkt
Annual exacerbation rate
Relevanz
2
Ergebnis53% reduction (p<0.001); FEV1 +98 mL.
Ortega HG, et al. N Engl J Med. 2014;371(13):1198-1207. 10.1056/NEJMoa1403290
Diskussion & Kritik
Defined SC mepolizumab 100 mg q4wk as the standard dose for severe eosinophilic asthma.